GeneDx Holdings Corp.

Unless otherwise stated in this Annual Report or the context otherwise requires, references to: GeneDx Holdings refer to GeneDx Holdings Corp., a Delaware corporation; Legacy GeneDx refer to GeneDx, LLC, a Delaware limited liability company, which we acquired on April 29, 2022 (the Acquisition ); Legacy Sema4 refer to Sema4 OpCo Inc., a Delaware corporation, which consummated the business combination with CM Life Sciences, Inc. ( CMLS ) on July 22, 2021 (the Business Combination ); Fabric Genomics refer to Fabric Genomics, Inc., a Delaware corporation, which we acquired on May 5, 2025 (the Merger ); and we, us and our, the Company and GeneDx refer, as the context requires, to GeneDx Holdings and its consolidated subsidiaries. The Company’s Class A common stock and public warrants are listed on the Nasdaq Global Select Market under the symbols WGS and WGSWW, respectively. Purpose At GeneDx, our mission is to empower everyone to live their healthiest life through genomics. GeneDx combines clinical expertise, advanced technology, and the proprietary GeneDx Infinity dataset to power the ExomeDx and GenomeDx tests ranked #1 by expert geneticists and granted FDA Breakthrough Device Designation enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity TM also fuels discovery for biopharma while supporting the network that we believe will drive the future of precision genetic medicine.